Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 in Relapsed/Refractory CD19+ B-cell Lymphoma
NCT03101709Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in B cell lymphoma, sponsored by Henan Cancer Hospital. Primary endpoint: Safety as assessed by the occurence of study related adverse events at 6 months. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03101709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101709.